Protara Therapeutics, Inc.

The momentum for this stock is not very good. Tradey thinks it is not wise to invest in Protara Therapeutics, Inc. .

News

Protara Therapeutics completes first cohort in Phase 2 trial of TARA-002

The Fly See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...\n more…

Protara Therapeutics announce results from THRIVE-1 study

Protara Therapeutics Announces Completion of First Cohort in Phase 2 STARBORN-1 Trial of TARA-002 in Pediatric Patients with Lymphatic Malformations

Globe Newswire TARA-002 demonstrated compelling efficacy and was generally well-tolerated Enrollment in additional cohorts underway with initial results expected in 1H'25 NEW YORK, Sept. 09, 2024 (GLOBE...\n more…

Protara Therapeutics Announces Results from THRIVE-1, a Prospective Observational Study Evaluating the Prevalence of Choline Deficiency and Liver Injury in Patients Dependent on Parenteral Su

Globe Newswire 78% of patients dependent on parenteral support were choline deficient, with 63% of these patients demonstrating liver dysfunction, including steatosis, cholestasis, and hepatobiliary injuryIV...\n more…

Protara Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Globe Newswire NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases...\n more…